ArticleClinical ophthalmology (Auckland, N.Z.)2026
Measurement of Acute Intraocular Pressure Elevation Immediately After Intravitreal Anti-VEGF Injection and Analysis of Prefilled Syringe Accuracy.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Short-Term Intraocular Pressure Changes After Intravitreal Aflibercept 8 mg via Prefilled Syringe.Ophthalmology and therapy · 2026Article
- Short-term intraocular pressure changes following intravitreal aflibercept 8 mg versus 2 mg in diabetic macular edema: a prospective observational study.Scientific reports · 2026Observational
- Systemic and ocular complications related to intravitreal administration of anti-VEGF agents.Medical hypothesis, discovery & innovation ophthalmology journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To compare and evaluate, across different agents, the risk of intraocular pressure (IOP) elevation after anti-VEGF therapy and the accuracy of prefilled syringes. Methods: Total of 175 eyes treated with anti-VEGF drugs were enrolled for this study. An accuracy evaluation of the prefilled syringes was conducted involving 25 participants, comprising 17 physicians and 8 nurses. The anti-VEGF agents including aflibercept 2 mg, aflibercept 8 mg, brolucizumab, faricimab, and ranibizumab-BS were assessed. IOP was measured before, and at 1 and 15 minutes after intravitreal injection, and analyzed separately for each drug. Furthermore, prefilled syringes of aflibercept 2 mg, brolucizumab, and ranibizumab-BS, as well as 1-mL syringes filled with saline solution, were equipped with 30-gauge needles, followed by careful removal of air. The weight of the saline discharged according to the scale marking was measured using an electronic balance. Results: At 1 min after intravitreal injection, the IOP was highest in the aflibercept 2 mg group, with a mean value of 52.8 mmHg. A mild inverse correlation was observed between axial length and IOP elevation at 1 min post-injection, suggesting that eyes with longer axial length exhibited less pronounced IOP increases. In the syringe accuracy analysis, the prefilled syringe of aflibercept 2 mg expelled a significantly larger volume, with a mean of approximately 0.076 mL, compared to other prefilled syringes. Conclusion: Intravitreal injection using the aflibercept 2 mg prefilled syringe may deliver approximately 1.5 times the intended volume into the eye. This may raise safety concerns, such as the risk of transient vision loss due to marked immediate IOP elevation, and may also affect clinical outcomes and the validity of clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.